Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
  • A61K9/7061—Polyacrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
  • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
  • C08F290/04—Polymers provided for in subclasses C08C or C08F
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
  • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
  • C08F290/04—Polymers provided for in subclasses C08C or C08F
  • C08F290/044—Polymers of aromatic monomers as defined in group C08F12/00
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
  • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
  • C08F290/04—Polymers provided for in subclasses C08C or C08F
  • C08F290/046—Polymers of unsaturated carboxylic acids or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
  • C09J151/00—Adhesives based on graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Adhesives based on derivatives of such polymers

Definitions

• the present invention is directed to a pressure sensitive adhesive useful in transdermal administration of pharmacologically active agents, in particular estrogen and/or progestin active agents .
• pharmacologically active agents in particular estrogen and/or progestin active agents .
• the transdermal delivery of therapeutic agents has been the subject of intense research and development for over 20 years. These efforts have resulted in the creation of several commercially successful products whose advantages over other dosage forms are well documented.
• the skin is an exceptionally well designed barrier. As a result, only a relatively small number of drug molecules are suitable for transdermal delivery, including hormones such as estrogen and/or progestin.
• the prior art does not provide a transdermal pressure sensitive adhesive which both serves as a satisfactory matrix for the delivery of an estrogen and/or progestin active agent as well as inhibiting the crystallization of such active agent in order to enhance the long-term effectiveness of the delivery system.
• transdermal adhesive which may be used with either an oily or water-soluble drug flux or skin permeation enhancer or mixtures of same. This avoids the need to use separate adhesive formulations depending upon whether the enhancer is oil or water-soluble.
• a pressure sensitive adhesive which possesses adequate compatibility with both oily and water-soluble percutaneous penetration enhancers and which may accordingly be used with advantage in a transdermal drug delivery device.
• a graft copolymer pressure sensitive adhesive comprised of a backbone polymer having a polymeric moiety grafted thereto, said graft copolymer comprising the reaction product of: •
• At least one A monomer consisting of a monomeric acrylic or methacrylic acid ester of a non-tertiary alcohol, said alcohol having from 1 to 30 carbon atoms, wherein at least about 30 percent by weight of said A monomer consists of a monomeric acrylic or methacrylic acid ester of a non-tertiary alcohol having at least 12 carbon atoms, and said at least one A monomer exhibiting an average number of carbon atoms in the alcohol portion of the total acrylic or methacrylic acid esters of at least 10, (2) optionally at least one B monomer,
• a polymeric graft moiety D containing repeat hydrophilic units preferably a polyether or polyester-based graft moiety.
• a transdermal drug delivery composition having pressure sensitive adhesive properties comprised of (1) a graft copolymer comprised of a (meth) acrylic ester backbone copolymer optionally including at least one N- vinyl lactam monomer and having a polymeric moiety grafted thereto containing hydrophilic repeat units, and (2) a pharmacologically active agent in homogeneous admixture with said macromer reinforced base polymer.
• a transdermal drug delivery system for administering a pharmacologically active agent comprising a flexible backing material impermeable to said pharmacologically active agent and an adhesive layer on at least a portion of said backing material, the improvement wherein said adhesive layer comprises a graft copolymer comprised of a (meth) acrylic ester backbone copolymer optionally including at least one N-vinyl lactam monomer and having a polymeric moiety grafted thereto containing hydrophilic repeat units.
• the present invention is directed to a pressure sensitive adhesive as well as a transdermal drug delivery composition comprised of a graft copolymer and transdermal delivery device utilizing such a composition.
• the graft copolymer pressure sensitive adhesive employed in the present invention is comprised of a backbone polymer having a polymeric moiety grafted thereto.
• the graft copolymer comprises the reaction product of at least one (meth) acrylic acid ester A monomer (as defined), at least optional B monomer, optionally a polymeric graft moiety C having a T n greater than 20°C, and a polymeric graft. moiety D containing hydrophilic repeat units.
• the graft copolymer includes at least one A monomer consisting of a monomeric (meth) acrylic acid ester of a non-tertiary alcohol where the alcohol portion has from 1 to 30 carbon atoms.
• Exemplary A monomers include but are not limited to esters of acrylic acid or methacrylic acid with non-tertiary alcohols such as l-butanol, 1- pentanol, 2-pentanol, 3-pentanol, 2-methyl-l- butanol, 1-methyl-l-pentanol, 2-methyl-l-pentanol, 3-methyl-l-pentanol, 2-ethyl-l-butanol, 3,5,5- trimethyl-1-hexanol, 3-heptanol, 2-octanol, 1- decanol, 1-dodecanol, etc.
• At least one A monomer formed from an alcohol having at least 12 carbon atoms is particularly desirable.
• Such exemplary A monomers include but are not limited to lauryl acrylate (C 12 ) , tridecylacrylate (C 13 ) , myristyl acrylate (C 14 ) , palmityl acrylate (C 16 ) , and stearyl acrylate (C 18 ) .
• Such monomers are known to those skilled in the art.
• an A monomer having a carbon chain of at least 12 carbon atoms has been found to enhance the compatibility of the adhesive with oily or non-water soluble drug flux or skin permeation enhancers which may be employed. Such enhancers have not been found to be particularly compatible with conventional transdermal adhesives containing a major portion of A monomers formed from alcohols having from 4 to 12 carbon atoms. While the use of A monomers formed from alcohols having from 4 to 12 carbon atoms in the adhesive of the present invention is appropriate, it is preferable for the at least one A monomer component to comprise at least 30 percent by weight of an A monomer formed from an alcohol having greater than 12 carbon atoms.
• the at least one A monomer component (if more than one A monomer is present) will exhibit an average number of carbon atoms in the alcohol portion of the total acrylic or (meth) acrylic acid esters of from 4 to 16, and preferably at least 10.
• One or more optional polymerizable B monomers may be incorporated in the copolymer which B monomer (s) is copolymerizable with the A monomer.
• Such additional B monomer (s) may be either hydrophilic or hydrophobic.
• Exemplary optional B monomers include vinyl monomers having at least one nitrogen atom.
• Such monomers include but are not limited to N-mono-substituted acrylamides such as acrylamide, methacrylamide, N- methylacrylamide, N-ethylacry lamide , N- methylolacrylamide, N-hydroxyethylacrylamide, and diacetone acrylamide; N , N-disubstituted acrylamides such as N,N-dimethylacrylamide, N,N- diethylacrylamide, N-ethy1-N-aminoethylacrylamide, N-ethy 1 -N-hydroxyethylacrylamide, N,N- dimethylolacrylamide , and N , N - dihydroxyethylacrylamide, etc.
• Other optional B monomers may include, for example, various vinyl monomers such as acrylic and methacrylic acid, methoxyethyl acrylate, or methacrylate, ethyoxyethyl acrylate or methacrylate, glycerol acrylate or methacrylate, hydroxyethyl methacrylate, hydroxypropyl methacrylate, beta-carboxyethyl acrylate, vinyl pyrrolidone and vinyl caprolactam (each of which also exhibit a T g of >20°C).
• various vinyl monomers such as acrylic and methacrylic acid, methoxyethyl acrylate, or methacrylate, ethyoxyethyl acrylate or methacrylate, glycerol acrylate or methacrylate, hydroxyethyl methacrylate, hydroxypropyl methacrylate, beta-carboxyethyl acrylate, vinyl pyrrolidone and vinyl caprolactam (each
• the at least one B monomer preferably comprises an N-vinyl lactam monomer.
• N- vinyl lactam monomers include but are not limited to N-vinyl-2-pyrrolidone; 5-methyl-N-vinyl-2- pyrrolidone; 5-ethyl-N-vinyl-2-pyrrolidone; 3,3- dimethyl-N-viny1-2-pyrrolidone; 3-methyl-N-vinyl- 2-pyrrolidone; 3-ethyl-N-vinyl-2-pyrrolidone; 4- methyl-N-vinyl-2-pyrrolidone; 4-ethyl-N-vinyl-2- pyrrolidone; N-vinyl-2-valerolactam; N-vinyl-2- caprolactam; and mixtures of any of the foregoing.
• the N-vinyl lactam is N-vinyl-2- pyrrolidone.
• the optional graft polymeric moiety C has a T greater than 20°C.
• Graft polymeric moiety C has the formula X-Z wherein X is a group copolymerizable with monomers A and B or capable of attachment to copolymerized A and B monomers and Z is a polymeric graft moiety having a T g greater than 20°C.
• the Z moiety is essentially unreactive under copolymerization conditions.
• the X moiety is an unsaturated polymerizable moiety the composition of which is not critical.
• the X moiety may comprise an amine or alcohol moiety (such as a monohydroxyl or monoamine moiety) which permits attachment of the macromer to a suitable functionality on previously- polymerized monomers A and B.
• the hydroxyl moiety can serve as a terminal reactive group by reaction with suitable moieties on the polymer backbone resulting from the use of monomers such as isocyanate-substituted (meth) acrylic acid, (meth) acrylic acid anhydride, etc.
• a variety of functional groups may be employed to attach the graft Z to the polymer backbone.
• Exemplary functional groups include but are not 0 0 0 it '/ limited to -C-0-CHR-CH 2 - ; -C-0-CH 2 CH 2 -NH-C-0-
• R is a hydrogen atom or a lower alkyl group.
• 3,842,059; 3,862,098; 3,862,101, 3,862,102 and 4,554,324 disclose polymerizable macromers which are suitable for use as graft moieties on a backbone polymer as defined.
• the polymeric moiety C is formed from a vinyl aromatic monomer such as styrene, alpha-methylstyrene, indene and p-tert- butylstyrene.
• the polymeric moiety Z may also be formed from vinyl toluene, acenaphthalene, acrylonitrile and methacrylonitrile; organic isocyanates including lower alkyl, phenyl, lower alkyl phenyl and halophenyl isocyanates; organic diisocyanates including lower alkylene, phenylene, and tolylene diisocyanates; lower alkyl and allyl acrylates and methacrylates, including methyl, t- butyl acrylates, and methacrylates; lower olefins, such as ethylene, propylene, butylene, isobutylene, pentene, hexene, etc.
• vinyl esters of aliphatic carboxylic acids such as vinyl acetate, vinyl propionate, vinyl octoate, vinyl oleate, vinyl stearate, vinyl benzoate, vinyl lower alkyl ethers; conjugated dienes such as isoprene and butadiene; 2-oxazolines such as 2- ethyl-2-oxazoline; and vinyl unsaturated amides such as acrylamide, methylacrylamide, N,N-di( lower alkyl) acrylamides such as N,N-dimethylacrylamide.
• polymer graft The selection of the specific polymerizable monomer for the polymer graft is not critical, since as the above listing suggests, a wide variety of monomers (and the resulting polymeric moieties) can be used with success as a polymeric graft in the claimed composition which meet the minimum T g requirement.
• the molecular weight of the graft polymeric moiety C is preferably sufficient to result in the formation of a "phase-separated" graft copolymer composition.
• the molecular weight of the graft polymeric moiety will be within the range of from 2,000 to 60,000, and will preferably range from 2,000 to 13,000.
• the macromer D also forms polymeric sidechains on the graft copolymer.
• the macromer D contains hydrophilic repeat units.
• the macromer may be represented by the formula X-(Y) -Z-R.
• X is as defined above and is a moiety copolymerizable with monomers A and B or, in the alternative, capable of attachment to polymerized monomers A and B, Y is a divalent linking group, Z is a homo- or copolymeric moiety essentially unreactive at copolymerization conditions which contains hydrophilic repeat units, R is a terminal group, and p is 0 or 1.
• a preferred Y divalent linking group is -C-, or a linking group which incorporates such a moiety.
• Additional Y linking groups which may be employed in connection with the present invention include but are not limited to the following moieties:
• the Z moiety is preferably selected from the group consisting of (but not limited to) a polypropylene or polyethylene oxide radical, a polyethyloxazoline radical such as a radical of poly (2-ethyl-2-oxazoline) , polyacrylic acid radical, polyvinyl alcohol radical, polyvinylpyrrolidone radical, polyvinyl caprolactam radical, polymethylvinyl ether radical or mixtures thereof.
• Exemplary D macromers formed from such radicals include but are not limited to ethoxylated or propoxylated hydroxy (C 1 _ 5 ) alkyl meth ( aery late) polymethy lviny 1 ether mono (meth) acrylate and beta-carboxyethyl acrylate.
• the molecular weight of the macromer used in the present invention is not critical but will generally range from about 300 to about 50,000, and preferably from about 300 to 3,000.
• the Z moiety is preferably comprised solely of one or more hydrophilic monomer radicals.
• the Z moiety may also be a copolymer of hydrophilic and hydrophobic monomers.
• any non-hydrophilic portion employed in such a Z copolymer is present in an amount of less than 50 percent by weight based on the weight of the macromer, and preferably less than 30 percent by weight.
• the macromer D is preferably represented by the formula:
• macromer D may be an ethoxylated or propoxylated hydroxy (C 1-5 ) alkyl
• CH 2 C - C - (0 - C m H 2m ) n - R I II R ⁇ 0 wherein R ⁇ is hydrogen or C ⁇ _ 5 alkyl and R is a terminal group. Preferably, is 2 or 3 and n is
• R is OH, C 1-5 alkyl or nonyl-phenol .
• macromer D may advantageously comprise a 2-carboxy(C 1 _ 5 ) alkyl acrylate of the formula: Rn o O ii
• CH 2 C - C - (C m H 2m - C - 0) n - R wherein R 2 is hydrogen or C 1-5 alkyl and R is a terminal group.
• m is 2 or 3 and n is 4 to 30, and R is H, OH, C 1 _ s alkyl or nonyl- phenol.
• macromer D may incorporate mixtures of polyether and polyester repeat units with advantage which ratios are non-critical to practice of the present invention.
• the macromer D may employ a variety of terminal groups R. While the terminal group may typically be OH or C 1-5 alkyl, it may be desirable to select a terminal group based on the functional character of the terminal group.
• suitable terminal groups include but are not limited to (1) acid/ionic groups such as carboxyl, phosphate or sulfate groups, (2) hydrophobic groups such as lower alkyl, phenyl or substituted phenyl, and (3) hydrophilic groups such as hydroxyl or amine groups.
• ionic end groups may be used to provide pH-dependent solubility characteristics for the copolymer.
• Hydrophobic terminal groups may be used to reduce the water solubility of the copolymer.
• copolymer of the present invention may be covalently or ionically- crosslinked in a conventional manner.
• Ionic terminal groups may be used to provide a desired degree of crosslinking; for example, by neutralizing acid moieties with metal hydroxides.
• High temperature performance may be enhanced by incorporating an acid functionality in conjunction with a ditertiary amine.
• Aqueous solution viscosities may be influenced by the presence of ionic terminal groups.
• the A monomer is present in the graft copolymer an amount of from 20 to 80 percent by weight
• the B monomer is present in an amount of from 3 to 30 percent by weight
• the optional C macromer is present in an amount of from 2 to 15 percent by weight
• the D macromer is present in an amount of from 5 to 60 percent by weight, based on the total weight of the respective components A, B, C, and D in the copolymer.
• a tackifier or plasticizer into the copolymer to enhance tack.
• Exemplary tackifiers include but are not limited to polyethylene glycol, polypropylene glycol, and suitable polyoxyethylene-based compounds.
• Suitable polyoxyethylene-based tackifiers are disclosed at column 6 of U.S. Patent No. 4,413,080, herein incorporated by reference in its entirety.
• Other suitable tackifiers include conventional hydrogenated rosin ester compounds.
• Polyalicyclic tackifiers include those based on aromatic copolymers of styrene, alpha-methyl styrene and indene followed by hydrogenation. Such tackifiers, if present, may be employed in an amount of up to about 50 percent by weight, based on the total weight of the composition.
• Plasticizers may be used in amounts of up to about 20% by wt.
• plasticizers include but are not limited to adipate and glutarate esters, hydrogenated rosin esters and reduced alcohol derivatives, as well as hydrogenated poly (aromatic) copolymers and mineral or paraffin oils.
• Preferred plasticizers include citric acid esters such as those marketed under the name Citroflex which include triethyl citrate, acetyltriethyl citrate, tri-n-butyl citrate, acetyltri-n-butyl citrate.
• the copolymer composition of the present invention may be prepared by any conventional polymerization technique, including (1) free radical-initiated copolymerization of components A and D and optionally B and C in the presence of a solvent, or (2) attachment of the macromer grafts to a preformed backbone polymer formed from copolymerized monomer A copolymerized with monomer B via reaction with a suitable functional group on the backbone polymer subsequent to formation of same.
• Suitable copolymerization temperatures range from about 20°C. to about 150°C. for periods of time of from 2 to 24 hours until the desired degree of conversion occurs. Upon completion of the copolymerization process, the solvent is removed and a tacky copolymer results having acceptable adhesive properties. If desired, a suitable crosslinking agent may be employed to increase the molecular weight of the adhesive if desired.
• composition of the present invention successfully overcomes the deficiencies of prior art transdermal adhesives in several ways.
• inclusion of an N-vinyl lactam monomer as a B monomer reduces the tendency of any pharmacologically active agent susceptible to crystallization (such as estrogen and/or progestin) present in the drug delivery system to crystallize within the system. This permits the active agent to remain effective over the entire period of time of delivery to the patient through the drug delivery device.
• the presence of the graft moieties enhances the ability of the adhesive system to retain its structural integrity and adhesive character during the period of use of the drug delivery device. More specifically, the presence of a graft macromeric moiety containing hydrophilic repeat units enhances the compatibility of any drug flux enhancer with the graft copolymer.
• Suitable active agents include those that are compatible with the administration system of the present invention and exhibit the expected benefit upon percutaneous administration.
• active agents include, without limitation, antibiotics, antipyretics, analgesics, anti- inflammatory drugs, antihistaminics, psychotropic drugs, coronary vasodilators, antiarrhythmics, antihypertensives, chemotherapeutic drugs, anticancer agents, antiemetics, vitamins, antispasmodics, antitussives, antifungal drugs, steroids, etc.
• exemplary of the most commonly transdermally-administered active agents are clonidine, estrodiol, nicotine, nitroglycerine and scopolamine, each commercially available in transdermal devices. See U.S. Patent No. 5,372,819, herein incorporated by reference, for a more detailed discussion of suitable percutaneous administered active agents.
• estrogen and progestin may be administered by means of the present invention.
• the estrogen component may be either a synthetic or natural estrogen.
• Exemplary estrogen compounds include ethinyl estradiol, 17B estradiol, mestranol, estradiol valerate, 11- nitrato estradiol, 7-alpha-methyl-ll-nitrato- estradiol, piperazine estrone sulfate, quinestranol and pharmaceutiically acceptable derivatives thereof.
• progestin components include progesterone, 17- hydroxyprogesterone , dihydroprogesterone, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethynodrel , ethynodioldiacetate, norgestrel, levo-norgestrel, gestodene, delta-15-levonorgestrel, norgestimate, 17-deacetyl norgestimate, nomegesterol, nesterone, desogestrel, and 3-keto-deogestrel.
• a graft copolymer as a transdermal adhesive matrix is taught by U.S. Patent No. 4,482,534.
• this patent is directed to a nitroglycerin adhesive preparation.
• the adhesive preparation disclosed in this patent may comprise a graft vinylpyrrolidone copolymer, either crosslinked or non-crosslinked.
• PCT publication WO 96/08229 also discloses a transdermal adhesive matrix comprised of a graft copolymer which may be used in association with estradiol or progestin.
• the disclosed adhesive does not achieve the balance of properties achieved by the present invention.
• the adhesive may be used with particular advantage in association with a percutaneous penetration enhancer in a transdermal drug delivery device.
• Percutaneous penetration enhancers have the ability to increase permeability of skin to transdermally-administered pharmacologically active agents. Such enhancers are well-known in the art, and are discussed at length in U.S. Patent Nos. 5,059,426 and 5,175,052, each herein incorporated by reference.
• such enhancers include but are not limited to surfactants (anionic, nonionic, cationic, zwitterionic) , lipophilic solvents (terpenes, lactams) , hydrophilic solvents (polyols, fatty acid esters, alcohols, sulfoxides) , etc.
• surfactants anionic, nonionic, cationic, zwitterionic
• lipophilic solvents Terpenes, lactams
• hydrophilic solvents polyols, fatty acid esters, alcohols, sulfoxides
• such enhancers are selected from the group consisting of sorbitols, ethoxylated alkyl phenols, glycerol, propylene glycol, polyethylene glycols, fatty acid esters, alcohols, and amines, and may be either water- soluble or non-water soluble (i.e. oily).
• the pressure sensitive adhesive of the present invention can be used with advantage upon admixture of percutaneous penetration enhancers with the base polymer to form a drug flux enhancer-tolerant pressure sensitive adhesive composition. That is, both oily or water-soluble percutaneous penetration enhancers can be admixed with the base polymer to maximize the ability of an incorporated pharmacologically active agent to be absorbed into the skin without adversely affecting the adhesive properties of the adhesive.
• the percutaneous penetration enhancer can be used in amounts up to about 40 percent by weight, based on the weight of the composition, without adversely affecting the physical integrity of the adhesive or its adhesive properties.
• the percutaneous penetration enhancer is either oil or water- soluble which result is not well-attained by conventional adhesives.
• the enhancer will be employed in an amount within the range of from 5 to 30 percent by weight, based on the weight of the composition.
• the adhesive of the present invention may be used with advantage in a variety of conventional transdermal drug delivery devices.
• Such devices may take many forms.
• such devices comprise a backing material and an adhesive layer on at least a portion of the backing material.
• a release liner covers the adhesive layer until use at which time the liner is removed and the adhesive layer placed on the skin.
• the backing material is impermeable to the pharmacologically active agent.
• the pharmacologically active agent may be contained in either a liquid reservoir within the backing layer, within a matrix layer on said backing layer disposed between the adhesive layer and the backing layer, or within a layer of the drug flux enhancer-adhesive composition of the present invention.
• the manner of formulation of such various transdermal drug delivery systems is within the ability of one skilled in the art.
• the pharmacologically active agent in homogenous admixture with the pressure sensitive graft copolymer, is present in an amount effective to provide the desired dosage to the patient.
• the active agent will be present in in an amount within the range of from 0.5 to 30 percent by weight, based on the total weight of the composition.
• One skilled in the art can readily determine the amount of pharmacologically active agent to employ in association with the graft copolymer to achieve the desired degree of administration.
• the adhesive of the present invention may also be used in association with a variety of body members (e.g., tapes, patches, strips, labels, etc.) to provide an adhesive assembly.
• the body member may be in the form of a backing material coated on at least one side thereof with the adhesive to provide an adhesive- backed sheet film or tape.
• Exemplary backing materials used in the production of such a product include but are not limited to flexible and inflexible backing materials conventionally employed in the area of pressure sensitive adhesives, such as creped paper, kraft paper, fabrics (knits, non-wovens, wovens) , foil and synthetic polymer films such as polyethylene, polypropylene, polyvinyl chloride, poly (ethylene terephthalate) and cellulose acetate, as well as glass, ceramics, metallized polymer films and other compatible sheet or tape materials.
• pressure sensitive adhesives such as creped paper, kraft paper, fabrics (knits, non-wovens, wovens)
• foil and synthetic polymer films such as polyethylene, polypropylene, polyvinyl chloride, poly (ethylene terephthalate) and cellulose acetate, as well as glass, ceramics, metallized polymer films and other compatible sheet or tape materials.
• the body member (e.g., in sheet form) may be coated in any conventional manner with the adhesive composition of the present invention, such as by roll coating, spray coating, extrusion coating, co-extrusion coating, hot melt coating by use of conventional coating devices.
• the adhesive of the present invention may be applied as a solution to at least one surface of the body member and the solvent subsequently removed to leave a tacky adhesive residue on the body member.
• the adhesive may be applied to the body member either in the form of a continuous layer or in discontinuous form.
• various polymeric adhesive compositions were prepared having the compositions described in the following Examples.
• EXAMPLE 1 A reaction mixture was prepared and 0.11 wt. % BPO was used as the catalyst. 30% of the mixture was charged to a 1-liter reaction vessel. Under a nitrogen atmosphere, the batch was heated to 72 °C over 15 minutes. After the initial 15 minutes, the remaining 70% of monomer/solvent mixture was added over 4 hours, maintaining a batch temperature of 71.5-74 °C. Upon completion of the addition, the reactants were polymerized for 1 additional hour to produce a tackifier-free pressure sensitive adhesive.
• the reactor feed mix consisted of the following components:
• Example 2 Ethyl acetate 4 7 . 4 . 3 0 Toluene 52 , . 70 EXAMPLE 2 The procedure of Example 1 was repeated using the following reactor feed components to produce a tackifier-free pressure sensitive adhesive with the exception that the reactants were added over 3.5 hours with a subsequent 1.5 hour reaction time:
• Example 3 The procedure of Example 1 was repeated using the following reactor feed components to produce a tackifier-free pressure sensitive adhesive with the exception that the reactants were added over 3.5 hours with a subsequent 1.5 hour reaction time:
• Example 1 The procedure of Example 1 was repeated using the following reactor feed components to produce a tackifier-free pressure sensitive adhesive, with the exception that the reactants were added over 3.5 hours with a subsequent 1.5 hour reaction time:
• Example 1 The procedure of Example 1 was repeated using the ' following reactor feed components to produce a tackifier-free pressure sensitive adhesive, with the exception that the reactants were added over 3 hours with a subsequent 1 hour reaction time:
• Example 6 The procedure of Example 5 was repeated with the exception that the following components were added to the completed polymer product of Example 5 to yield a crosslinked adhesive:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Dermatology (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Endocrinology (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Medicinal Preparation (AREA)
• Compositions Of Macromolecular Compounds (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Macromonomer-Based Addition Polymer (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=27122609

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (12)

Family Cites Families (6)

• 1998
  • 1998-02-23 JP JP53672598A patent/JP2001513124A/ja active Pending
  • 1998-02-23 CA CA002276339A patent/CA2276339A1/en not_active Abandoned
  • 1998-02-23 KR KR1019997006608A patent/KR20000070375A/ko not_active Application Discontinuation
  • 1998-02-23 WO PCT/US1998/002696 patent/WO1998037111A1/en not_active Application Discontinuation
  • 1998-02-23 EP EP98914224A patent/EP0961794A1/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events